KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBIT Margin (2016 - 2025)

Historic EBIT Margin for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to 109.95%.

  • TherapeuticsMD's EBIT Margin rose 973600.0% to 109.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 61.8%, marking a year-over-year increase of 3564900.0%. This contributed to the annual value of 270.3% for FY2024, which is 3843100.0% up from last year.
  • Latest data reveals that TherapeuticsMD reported EBIT Margin of 109.95% as of Q3 2025, which was up 973600.0% from 73.0% recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's EBIT Margin ranged from a high of 104.95% in Q4 2024 and a low of 4269.25% during Q2 2022
  • Its 5-year average for EBIT Margin is 971.35%, with a median of 221.63% in 2025.
  • In the last 5 years, TherapeuticsMD's EBIT Margin tumbled by -41163100bps in 2022 and then soared by 37035800bps in 2023.
  • Quarter analysis of 5 years shows TherapeuticsMD's EBIT Margin stood at 189.48% in 2021, then surged by 137bps to 70.65% in 2022, then crashed by -554bps to 320.92% in 2023, then soared by 133bps to 104.95% in 2024, then tumbled by -205bps to 109.95% in 2025.
  • Its last three reported values are 109.95% in Q3 2025, 73.0% for Q2 2025, and 221.63% during Q1 2025.